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Abstract 
Article History 
 
Churg-Strauss syndrome (CSS) is a systemic disorder characterized by asthma, transient 
pulmonary infiltrates, hypereosinophilia, and systemic vasculitis. Eosinophilicvasculitis may 
involve multiple organ systems, including the lungs, heart, skin, gastrointestinal tract and 
nervous system. Thus allergy and angiitis are the two hallmarks of CSS. Conditions in the 
differential diagnosis of CSS include Wegener's granulomatosis (WG), drug reactions, 
bronchocentricgranulomatosis, eosinophilic granuloma, fungal and parasitic infections, and 
malignancy. Onset typically occurs in patients aged from 15 to 70 years.On presentation, 
patients often have pulmonary infiltrates on chest x-ray, but they may also have sinusitis, 
neuropathy, constitutional symptoms, or gastrointestinal or cardiac manifestations. It is 
important to establish a tissue diagnosis by biopsy and exclude other diseases in the 
differential diagnosis of CSS because treatment differs significantly from that of other 
eosinophilic lung diseases. Untreated, CSS may have a dire prognosis, but treatment with 
corticosteroids or cytotoxic agents, or both,usually results in clinical remission. Although the 
exact etiology of CSS is unknown, this syndrome is likely believed to represent an 
autoimmune process because of the prominence of allergic features and the presence of 
immune complexes, heightened T-cell immunity and altered humoral immunity, as shown by 
elevated immunoglobulin (Ig) E and rheumatoid factor. Treatment consists of glucocorticoid 
(GC)-monotherapy, data on outcome and affectivity is lacking on other immunosuppressive 
regimens such as cyclophosphamide (CP) or GC plus CP. Treatment with INF-alpha has 
been effective in patients refractory to GC plus CP. 
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Introduction 
Churg-Strauss syndrome (CSS) is a systemic disorder 
characterized by asthma, transient pulmonary infiltrates, 
hypereosinophilia, and systemic vasculitis. Eosinophilic 
vasculitis may involve multiple organ systems, including the 
lungs, heart, skin, gastrointestinal tract and nervous system. 
The three main histological features found on the pathological 
examination of CSS cases are extravascular granulomas, 
tissue eosinophilia, and necrotizing vasculitis. Thus allergy and 
angiitis are the two hallmarks of CSS. The Churg Strauss 
Syndrome is a rare condition, which causes inflammation in 
blood vessels, restricting the blood flow to various body 
organs. Though the disease may affect any body organ, it is 
seen that usually it is the lungs, nerves and skin which are 
most affected. The disease may cause temporary or 
irreversible damage to these organs.The most common feature 
of Churg Strauss Syndrome is asthma, also known as Allergic 
Granulomatosis. The disease is also known to show a type of 
tissue destroying inflammatory response called granuloma. 
Churg Strauss Syndrome is an autoimmune vasculitis, leading 
to necrosis, involving the blood vessels of the lungs, 
gastrointestinal system, peripheral nerves, heart, skin and 
kidneys. Churg-Strauss syndrome is rare. The cause of this 
syndrome is not known. But it involves an abnormal over-
activation of the immune system in a person with underlying 
bronchospastic lung disease (asthma).While Churg-Strauss 
syndrome has been reported to be associated with certain 
asthma medications, called leukotriene modifiers. The disease 
can occur at any age, but it's more commonly diagnosed in 
middle-aged people. People older than 65 are unlikely to 
develop Churg-Strauss syndrome. Other common names for 
CSS are allergic granulomatosis and allergic angiitis. Churg-
Strauss syndrome causes fever, weight loss, and sinus or 
nasal passage inflammation in the patient with asthma.Almost 
all people with CSS have increased numbers of "allergic type" 
blood cells called eosinophils. Eosinophils are a type of white 
blood cell. Normally, eosinophils make up 5% or less of the 
total white blood cell count. In CSS, eosinophils usually make 
up more than 10% of the total white blood cell count. In 
addition, most biopsies contain clusters of cells called 
"granulomas" that may or may not involve blood vessels. The 
granulomas often include eosinophils and are therefore called 
"allergic granulomas." In fact, another name for CSS is allergic 
granulomatosis. Some of the most serious manifestations of 
CSS are related to the presence of vasculitis. Other names for 
this disorder are Allergic Angiitis and Granulomatosis, Allergic 
Granulomatosis and Angiitis, Eosinophilic Granulomatous 
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Vasculitis, Churg-Strauss Vasculitis [1, 2]. Churg-Strauss 
syndrome is rare and is defined by six criteria:  
(1) Bronchial asthma;  
(2) Eosinophilia 10% by differential white cell count;  
(3) Mono- or polyneuropathy;  
(4) Nonfixed pulmonary infiltrates on chest radiography;  
(5) Paranasal sinus abnormalities;  
(6) Biopsy containing blood vessels with extravascular 
eosinophils.  
Presence of 4 out of 6 of these criteria has 99.7% 
specificity and 85% sensitivity for Churg-Strauss [3]. 
What is vasculitis? 
Vasculitis is a general medical term that refers to 
inflammation of the blood vessels. When blood vessels 
become inflamed, they can stretch, become thin-walled, or 
narrow in size. When they weaken and stretch in size, 
aneurysms can develop. (An aneurysm is an abnormal blood-
filled expansion of a blood vessel.) When they thin, the walls 
can rupture and blood leaks into tissue. Vasculitis can also 
cause blood vessels to narrow to the point of closing. Organs 
can be damaged from the loss of oxygen and nutrients that 
were being supplied by the blood. 
History 
First Description Churg-Strauss Syndrome (CSS) is a 
systemic vasculitis.This disease was first described in 1951 by 
Dr. Jacob Churg and Dr. Lotte Strauss [as a syndrome 
consisting of “asthma, eosinophilia an excessive number of 
eosinophils in the blood], fever, and accompanying vasculitis of 
various organ systems”when they reviewed a number of 
autopsy cases that were previously classified as 
polyarteritisnodosa. CSS shares many of the clinical and 
pathological features of polyarteritisnodosa (“PAN”, another 
type of vasculitis). Churg and Strauss discovered that the 
presence of granulomas as well as the abundance of 
eosinophils distinguished this disease from PAN. Although no 
universal agreement on CSS criteria has been reached so far, 
the most commonly used criteria are those developed by the 
American College of Rheumatology (ACR). The ACR criteria 
include both clinical and pathological features and classify CSS 
as the presence of four of the following six features: asthma, 
eosinophilia, neuropathy, pulmonary infiltrates, paranasal sinus 
abnormality and eosinophilic vasculitis [3]. 
Frequency 
Onset typically occurs in patients aged from 15 to 70 
years and the disease affects both males and females. The 
mean annual incidence in England is 2.4 per million 
inhabitants. The estimated prevalence of CSS in Norway is 1.3 
per 100,000 inhabitants compared to 5.3 for WG. The annual 
incidence of the disorder is estimated at 2.4-4 cases per million 
general population, while among asthma patients, an average 
of 34.6 cases per million asthma population has been reported 
[4].A recent German population-based epidemiological study of 
a population of nearly 5 million people revealed an incidence of 
1 per year per one million compared to 8 for WG. In another 
German study, the period prevalence rate of CSS in 1994 was 
7 per one million compared to 58 for WG.Although CSS has 
long been considered as a rare disease, there has been a 
recent increase in case reports in association with different 
asthma therapies. This has raised the questions of how rare 
this disease truly is and whether incidence has indeed 
increased in association with various forms of asthma therapy. 
In particular, CSS in association with asthma therapy was first 
reported in 1998 in patients receiving zafirlukast, but there 
have since been several reports of the syndrome in association 
with both montelukast and panlukast, as well as with various 
inhaled corticosteroids. 
Symptoms 
 Respiratory symptoms- The most common presenting 
manifestation of CSS is asthma, although as many as 2% of 
patients may develop airway symptoms after the onset of 
systemic vasculitis. Asthma often occurs in individuals who 
have no family history of atopy. It is severe and requires 
treatment with oral corticosteroids to control symptoms, 
which may lead to suppression of vasculitic symptoms. In 
addition the more common symptoms of cough, dyspnea, 
sinusitis, and allergic rhinitis, alveolar hemorrhage and 
hemoptysis may also occur [5].  
 Neurological symptoms- Neurological involvement is the 
second most common manifestation and occurs in 
approximately 78% of patients. Mononeuritis multiplex most 
commonly involves the peroneal nerve but may involve the 
ulnar, radial, internal popliteal and occasionally, cranial 
nerve. Isolated weakness, such as foot drop, is a common 
manifestation. Polyneuropathy often develops in the 
absence of treatment and may be symmetric or asymmetric 
[5]. Cerebral haemorrhage and infarction may also occur 
and are important causes of death. Despite treatment, 
neurological sequelae do not often completely resolve. 
 Dermatologic symptoms- Approximately half of CSS patients 
develop dermatological manifestations. These include 
palpable purpura, skin nodules, urticarial rashes, and livedo. 
They usually present on the limb surfaces but can affect any 
part of the body. 
 Cardiovascular symptoms- The heart is a primary target 
organ in CSS and its involvement often portends a worse 
prognosis. Granulomas, vasculitis and widespread 
myocardial damage may be found on biopsy or at autopsy, 
and cardiomyopathy and heart failure may be seen in up to 
half of all patients but are often at least partially reversible. 
Acute pericarditis, constrictive pericarditis, myocardial 
infarction, and other electrocardiographic changes may 
occur [6]. 
 Gastrointestinal symptoms- Gastrointestinal symptoms are 
common in CSS. They often consist in an eosinophilic 
gastroenteritis characterized by abdominal pain, diarrhoea, 
gastrointestinal bleeding, and colitis. Ischemic bowel, 
pancreatitis, and cholecystitis also have been reported in 
association with CSS and usually portend a worse prognosis 
[7]. 
 Renal symptoms- Renal involvement may include 
proteinuria, glomerulonephritis, interstitial nephritis, and (but 
seldom) renal failure. Renal biopsy may show focal 
segmental glomerulonephritis, crescents or other necrotizing 
features. Systemic hypertension is also common. 
 Constitutional Symptoms- Constitutional symptoms are very 
common in CSS and include weight loss of 10 to 20 lb, 
fevers (commonly higher than 38˚C for 2 weeks), and diffuse 
myalgias and migratory polyarthralgias. Myositis may be 
present, with evidence of vasculitis on muscle biopsy. 
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 Other symptoms- Constitutional symptoms are very common 
in CSS and include weight loss of > 10% of the body weight, 
fever (commonly higher than 38° for 2 weeks), and diffuse 
myalgias and migratory polyathralgias. Myositis may be 
present with evidence of vasculitis on muscle biopsy. 
(Figure-1)
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1- Skin involvement in Churg-Strauss syndrome (CSS).Biopsy showed vasculitis of the skin and abundant eosinophils, which are 
characteristic in CSS 
 
Clinical description 
CSS has been divided into 3 distinct phases, which may 
or may not be sequential. The prodromal phase is 
characterized by asthma with or without allergic rhinitis. The 
second phase is marked by peripheral blood eosinophilia and 
eosinophilic tissue infiltration producing a picture similar to 
simple pulmonary eosinophilia (Loeffler’s syndrome), chronic 
eosinophilic pneumonia, or eosinophilic gastroenteritis. The 
third, vasculitic phase may involve any organ of these organs: 
lung, heart, peripheral nervous system, kidney, lymph nodes, 
muscle, and skin. Skin involvement occurs in more than two 
thirds of patients. 
History-The 3 phases—allergic, eosinophilic, and 
vasculitic—do not necessarily follow one another in any 
particular order. Symptoms depend on the phase and organ 
systems involved. A careful history should include medication 
usage, infectious symptoms, and/or pre-existing disease [8]. 
1. Allergic phase of Churg-Strauss syndrome (allergic 
granulomatosis) 
 Rhinitis, sinus pain, headache 
 Cough 
 Wheezing 
2. Eosinophilic phase of Churg-Strauss syndrome 
(allergic granulomatosis) 
 General - Weight loss, fever, sweats 
 Gastrointestinal - Abdominal pain, diarrhoea, 
bleeding 
 Pulmonary - Cough 
3. Vasculitic phase of Churg-Strauss syndrome 
(allergic granulomatosis) 
 General - Malaise, lassitude, fever 
 Cardiac - Chest pain, dyspnoea 
 Cutaneous - purpura, papules 
 Pulmonary - Cough, hemoptysis 
 Rheumatologic - Arthralgia, arthritis, myalgia 
 Neurologic - Weakness, numbness 
Physical- Clinical findings in Churg-Strauss syndrome 
(allergic granulomatosis) vary depending on the phase and 
organ systems involved [9]. 
1. Allergic phase Churg-Strauss syndrome (allergic 
granulomatosis) 
 Nasal polyps 
 Wheezing 
 Cough 
 Rhinitis 
 Sinus tenderness 
2. Eosinophilic phase Churg-Strauss syndrome 
(allergic granulomatosis) 
 General - Weight loss, fever, sweats 
 Pulmonary - Cough, hemoptysis, rales, 
rhonchi 
 Gastrointestinal - Rebound, masses, 
obstruction, ascites, bleeding 
3. Vasculitic phase Churg-Strauss syndrome (allergic 
granulomatosis) 
 Constitutional symptoms - Fever, weight loss, 
adenopathy 
 Cardiac - Gallop, pericardial friction rub, 
jugular venous distension, peripheral edema 
 Pulmonary - Rales, rhonchi 
 Nervous system - Mononeuritis multiplex, 
diffuse peripheral neuropathy (most often in a glove-and-
stocking distribution), loss of a visual field, cerebral 
hemorrhage, infarction 
 Renal - Mild proteinuria and hematuria 
 Genitourinary - Obstructive uropathy 
 Ocular - Episcleritis, panuveitis, marginal 
corneal ulceration, conjunctival infiltration, retinal 
infarction 
 Musculoskeletal - Joint swelling, muscle 
tenderness 
 Cutaneous 
 Erythematous macules and papules at times 
resembling urticaria: Papules are most commonly located 
symmetrically on the extremities and scalp. 
 Hemorrhagic lesions, including petechiae, 
extensive ecchymoses, and hemorrhagic bullae 
 Subcutaneous nodules, facial edema, and 
livedo reticularis. 
Causes 
The etiology of Churg-Strauss syndrome (allergic 
granulomatosis) remains unclear. Several triggers are 
suspected, including environmental factors and medications. 
Inhaled allergens, vaccinations, infections (both bacterial and 
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parasitic), and prescription drugs (eg, carbamazepine, quinine, 
macrolides, corticosteroid-sparing drugs used to treat asthma) 
have all been implicated. A class of medications known as 
leukotriene inhibitors (montelukast, pranlukast, zafirlukast) has 
also been associated with Churg-Strauss syndrome (allergic 
granulomatosis). However, whether they are a direct cause or 
simply associated with the disease remains unclear at this 
time. Substantial tapering of corticosteroids with the use of 
leukotriene modifiers may allow unmasking of a previously 
unsuspected underlying disease, but some patients have never 
been on corticosteroids [10]. 
Another possible drug association with Churg-Strauss 
syndrome (allergic granulomatosis) is omalizumab, an anti-
immunoglobulin E (IgE) antibody used to treat asthma. Once 
again, whether omalizumab use is truly responsible for Churg-
Strauss syndrome (allergic granulomatosis) or simply unmasks 
it after corticosteroid tapering remains unclear [11, 12]. 
A foreign or infectious agent has been suggested to 
initiate an inflammatory cascade in an individual with a 
susceptible genetic background. The inflammation then leads 
to eosinophilia. High levels of cytotoxic enzymes released by 
eosinophils have been found in the urine, sera, and broncho-
alveolar lavage fluids of Churg-Strauss syndrome (allergic 
granulomatosis) patients. These enzymes could result in 
oxidative tissue damage [13]. ANCA antibodies activate 
neutrophils in vitro, producing greater quantities of reactive 
oxygen species, which may result in endothelial cell damage. 
ANCA-positive patients typically have more prominent 
vasculitic manifestations [10]. However, the etiology of Churg-
Strauss syndrome (allergic granulomatosis) remains 
incompletely understood, particularly in ANCA-negative 
patients. 
Pathology 
Whereas immune complex deposition was initially 
favoured as the mechanism of vascular injury in CSS (immune-
complex vasculitis), we know from more recent studies that 
most cases show no evidence of immune protein deposition in 
the vascular wall. In their series, Hattori et al. (1999) clearly 
demonstrated that IgG and C3d deposits are seen only 
occasionally in epineuronal vessel walls of the sural nerve 
(pauci immune vasculitis) [14].Peen et al. (2000) recently 
demonstrated thepresence of major basic protein in muscle 
fibers undergoing necrosis in a small bowel biopsyspecimen 
from CSS and discussed the role of other eosinophilic granule 
proteins such as ECP (eosinophil cationic protein) and 
eosinophilderived neurotoxin (EDN) in the underlying 
pathological process [15]. These findings are in keeping with 
the high levels of serum ECP and the excretion of urinary EDN 
in patients with CSS and reflect ongoing in vivo eosinophil 
degranulation in active disease due to cell activation. In a case 
report these authors mention that serial measurements of 
plasma IL-4, IL-5, and IL-13, serum ECP and blood and urine 
EDN clearly revealed that IL-13 and EDN, but not IL-4, IL-5, or 
ECP, paralleled the elevated non-specific inflammatory 
markers. These results contrast with the findings of others 
concerning ECP and IL-5. In another case report, IL-5 and 
ECP were found to be elevated in active CSS and to decline 
after treatment with interferon a (IFN-a) in a therapy (GC plus 
cyclophosphamide (CP))-resistant situation. Investigating the 
cytokine production pattern of T-cell lines (TCL) in CSS, Kiene 
et al. (2001)found significant differences between CSS and 
WG with respect to phenotype and cytokine profiles, as well as 
between CSS and healthy controls (HC). Classification of the 
TCL according to phenotype and IFN-alpha: IL-4 ratio revealed 
a polarization toward a CD4+, Th0 pattern in patients with 
CSS, compared with a CD8+, Th1 pattern in patients with WG, 
and a CD4+, Th1 pattern in HC. Moreover, a significant 
increase in IL-4 and IL-13 production was found in TCL of 
patients with CSS versus TCL derived from patients with 
another granulomatous disease (e.g WG). In addition, there 
was a positive correlation between IL-4 production and the 
eosinophil count in CSS, further substantiating the hypothesis 
that CSS is a Th2mediated disease, which in turn activates 
eosinophils and thus mediates the tissue damage [16]. In T 
cells the CD95/CD95 ligand system is a major pathway of 
apoptotic cell death and thus essential for prevention of 
lymphoproliferativedisorders and autoimmunity. Soluble CD95 
was identified as a survival factor for eosinophils which 
rescued them from apoptosis in the absence of growth factors 
in vitro. Given the role of eosinophils as effector cells in CSS, 
these findings suggest that soluble CD95 may be 
mechanistically involved in the disease. The same authors 
found recurrent oligoclonal T-cell expansions in 5 out of 7 CSS 
patients; all using a Vb-gene from the Vb21 family associated 
with similar CDR3 motifs, indicating the predominance of T-cell 
clones with a similar specificity in these patients. This contrasts 
markedly with the clonal proliferation of type 2 helper T cells in 
hypereosinophilic syndrome. These abnormal T cell clones 
produce IL5 in idiopathic eosinophilia. (Figure- 2) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2- Two tissue biopsy specimens from patients with Churg-Strauss syndrome, demonstrating extensive infiltration of the organs by eosinophils. 
The image on the left is a kidney biopsy specimen showing eosinophil infiltration, and the one on the right shows a lung biopsy specimen with 
eosinophil infiltration 
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Laboratory Abnormalities 
Systemic eosinophilia is the hallmark laboratory finding in 
patients with CSS and reflects the likely pathogenic role that 
the eosinophil plays in this disease. Eosinophilia greater than 
10% is one of the defining features of this illness and may be 
as high as 75% of the peripheral white blood cell count. It is 
present at the time of diagnosis in more than 80% of patients 
but may respond quickly (often within 24 hours) to initiation of 
systemic corticosteroid therapy. Even in the absence of 
systemic eosinophilia, tissue eosinophilia may be present. 
Although not specific to CSS, ANCA are present in up to two 
thirds of patients, mostly with a perinuclear staining pattern 
[17]. Other nonspecific laboratory abnormalities that may be 
present in patients with CSS include a marked elevation in 
erythrocyte sedimentation rate, normochromic normocytic 
anaemia, elevated IgE levels, hypergammaglobulinemia, and 
positive rheumatoid factor and antinuclear antibody. Broncho-
alveolar lavage often reveals significant eosinophilia, which 
may be seen in other eosinophilic lung diseases. Similarly, 
pulmonary function testing often reveals an obstructive defect 
similar to asthma. 
Radiographic Features 
Radiographic chest abnormalities are extremely common 
in CSS and consist of bilateral nonsegmental, patchy infiltrates 
that often migrate and that may be interstitial or alveolar in 
appearance. Reticulonodular and nodular disease without 
cavitation can be seen, as can pleural effusions and 
hilaradenopathy. The most common thin-section computed 
tomographic (CT) findings include bilateral ground-glass 
opacity and airspace consolidation that is predominantly 
subpleural and surrounded by the ground-glass opacity [18]. 
Other CT findings include bronchial wall thickening, 
hyperinflation, interlobular septal thickening, lymph node 
enlargement, and pericardial and pleural effusions. 
Angiography is often used diagnostically and may show signs 
of vasculitis in the coronary, central nervous system, and 
peripheral vasculature. 
Diagnosis and Differential Diagnosis 
Several criteria have been used to classify CSS.However, 
to diagnose this condition, a combination of clinical, laboratory, 
pathologic, and radiographic criteria must be used. Generally, 
the presence of vasculitis and eosinophilia in an individual with 
airway obstruction is enough to make a diagnosis of CSS. 
Although a biopsy specimen with eosinophilic vasculitis is the 
best diagnostic test and desired in most cases, noninvasive 
surrogates, including electromyogram (EMG), nerve 
conduction studies, or perinuclear ANCA, often can be used to 
support the diagnosis. EMG and nerve conduction studies are 
done when there is muscle pain or weakness or evidence of 
neuropathy. Testing is done in affected areas but may be 
considered for no affected areas if there is any suspicion of 
abnormality in other loci. The most commonly biopsied sites 
include the skin, nerve, and muscle, although pathologic 
specimens may be obtained from biopsy of any affected organ 
system, including the lung (by open-lung or thoracoscopic 
biopsy; transbronchial biopsy is generally not helpful), heart (by 
endomyocardial biopsy), gastrointestinal tract (endoscopically), 
liver, or kidney. When diagnosing CSS, it is generally best to 
satisfy at least four of the six ACR criteria, which yields a 
sensitivity of 85% and a specificity of 99.7%. However, several 
other eosinophilic lung conditions may present with similar 
findings and constitutional symptoms (Table). For instance, 
patients with allergic bronchopulmonaryaspergillosis or chronic 
eosinophilic pneumonia may present with airway obstruction, 
sinus disease,eosinophilia, and pulmonary infiltrates, but they 
do not necessarily have end-organ evidence of vasculitis that 
would differentiate them as having CSS. Other conditions in 
the differential diagnosis of CSS include Wegener’s 
granulomatosis, drug reactions, bronchocentricgranulomatosis, 
eosinophilic granuloma, fungal and parasitic infections, and 
malignancy. Although each of these disorders may meet ACR 
criteria for CSS, the treatment algorithm differs significantly for 
each of these conditions; therefore, it is extremely important to 
obtain tissue when the diagnosis is unclear before proceeding 
with therapy (Table-1). 
 
Table 1. Diseases Associated With Pulmonary Infiltrates and Eosinophilia in the Differential Diagnosis of Churg-Strauss Syndrome 
S.No Associated Disease 
1 Churg-Strauss syndrome 
2 Acute eosinophilic pneumonia 
3 Allergic bronchopulmonaryaspergillosis (ABPA) 
4 Asthma 
5 Bronchocentricgranulomatosis 
6 Chronic eosinophilic pneumonia 
7 Eosinophilic granuloma/histiocytosis X 
8 Drug reactions 
9 Infections: bacterial, fungal, mycobacterial, and parasitic 
10 Malignancy 
11 Wegener’s granulomatosis 
 
Treatment 
The use of cytotoxic agents and cyclosporine in the 
treatment of autoimmune diseases was reviewed following a 
Clinical Staff Conference held in 1997 at the National Institutes 
of Health, USA. Churg-Strauss syndrome (CSS) is typically a 
corticosteroid-responsive disease; hence, they are first-line 
therapeutic agents. Most patients respond to corticosteroid 
monotherapy. Intravenous corticosteroids should be 
considered for patients with extensive disease. Dramatic 
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response to therapy may be observed with improvement in 
eosinophilia counts, reduction of the erythrocyte sedimentation 
rate (ESR), and reduction in muscle enzyme levels within 1-2 
weeks of initiation of treatment. Corticosteroids may be tapered 
once clinical improvement occurs. Importantly, note that 
patients with Churg-Strauss syndrome (allergic 
granulomatosis)–related neuropathy respond more slowly to 
treatment. Residual asthma or other symptoms may require 
the continuation of low-dose prednisone therapy. 
Cyclophosphamide should be initiated in severely ill patients 
who do not respond to initial therapy. Patients with life-
threatening disease or those at risk of organ failure are 
potential candidates. The addition of cyclophosphamide 
appears to improve outcomes and reduces the incidence of 
relapses. For patients with systemic disease who are not at 
risk for major organ failure or death, methotrexate (MTX) may 
be given as a corticosteroid-sparing agent to reduce the 
cumulative dose. Other immune-modulatory medications 
include azathioprine (AZA) and mycophenolatemofetil, which 
may also be used as corticosteroid-sparing agents [19].Agents 
that block tumour necrosis factor (TNF), such as infliximab and 
etanercept, have been used for a limited period in severe life-
threatening cases. These agents, when combined with 
corticosteroids or other immunomodulatory agents, greatly 
increase the risk of infection due to immunosuppression. More 
data are needed to determine whether these drugs have a 
favourable risk-to-benefit ratio for use in Churg-Strauss 
syndrome (allergic granulomatosis) patients. Another 
infrequently used therapy is recombinant interferon (IFN) alfa, 
which can be effective when given on a short-term basis in 
otherwise refractory cases. One anecdotal case report has 
described the use of rituximab in a patient with recalcitrant 
Churg-Strauss syndrome (allergic granulomatosis). In the 
future however the targeting of cytokines, e.g. with antibodies 
against IL5 as is done in asthma, may improve our treatment 
protocols [20, 21]. 
Medications-  
a. Corticosteroids- Methylprednisolone, Prednisolone. 
b. Immunomodulators- Methotrexate, Azathioprine, 
Cyclosporine, Interferon alfa 2a and 2b. 
c. Alkylating agents- Cyclophosphamide, 
Chlorambucil. 
d. Anti-TNF agents- Infliximab, Etanercept. 
Prognosis 
Most patients diagnosed with CSS have previously been 
diagnosed with asthma, rhinitis, and sinusitis and have 
received treatment with inhaled or systemic corticosteroids. 
Because these agents are also the initial treatment of choice 
for CSS, institution of these therapies in patients with CSS who 
are believed to have severe asthma may delay the diagnosis of 
CSS because signs of vasculitis may be masked [22]. 
Treatment with corticosteroids (starting at 1 mg/kg and 
tapering over 3 to 6 months) dramatically alters the course of 
CSS: up to50% of those who are untreated die within 3 months 
of diagnosis,15 whereas treated patients have a 6-year 
survival of over 70%. Common causes of death include heart 
failure, cerebral hemorrhage, renal failure, and gastrointestinal 
bleeding. Recent data suggest that clinical remission may be 
obtained in over 90% of treated patients; approximately 25% of 
those patients may relapse, often due to corticosteroid 
tapering, with a rising eosinophil count heralding the relapse 
[23].Myocardial, gastrointestinal, or renal involvement most 
often portends a poor prognosis. In such cases, or if there is no 
improvement with standard doses of corticosteroids, treatment 
with higher doses (1–1.5 mg/kg) of corticosteroids for longer 
time periods or the addition of cytotoxic agents such as 
cyclophosphamide is often warranted. Although survival does 
not differ between patients treated with cyclophosphamide and 
those not treated with cyclophosphamide, its use isassociated 
with a reduced incidence of relapse and animproved clinical 
response to treatment [24, 25]. 
Conclusion 
CSS is a relatively rare multisystem disorder that is 
characterized by airway obstruction, pulmonary infiltrates, 
systemic eosinophilia, sinusitis, neuropathy, constitutional 
symptoms, and eosinophilic vasculitis of several organs, 
including the lungs, heart, gastrointestinal tract, and kidneys. It 
is important to establish a tissue diagnosis by biopsy to 
exclude other diseases in the differential diagnosis, because 
treatment options differ significantly from those of other 
eosinophilic lung diseases. Untreated, CSSmay have a dire 
prognosis, but treatment with corticosteroids or cytotoxic 
agents, or both, usually results in clinical remission of the 
disease. Although it is believed that the eosinophil plays a 
central role in the pathogenesis of CSS, the etiology of this 
syndrome remains unknown. Reports of CSS cases in 
association with the use of leukotriene modifiers and inhaled 
corticosteroids have increased, but no causative role for these 
agents in the pathogenesis of CSS has been firmly 
established. Because the etiology of CSS remains unclear, it is 
important for physicians to report suspected cases to 
pharmaceutical companies and to the US Food and Drug 
Administration. Careful diagnosis and thorough understanding 
of CSS will enable clinicians to make sound treatment 
decisions and to provide effective care for patients with this 
disease. 
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